LINKER-MM1: Longer-term follow-up and subgroup analyses

Long-term follow-up data from the phase I/II LINKER-MM1 trial (NCT03761108), evaluating linvoseltamab for the treatment of relapsed/refractory multiple myeloma (RRMM), were published in Clinical Lymphoma, Myeloma & Leukemia by Lee et al. The analysis included 117 patients treated at the 200 mg linvoseltamab dose level (phase I, n = 12; phase II, n = 105). 

Key data: At a median follow-up of 21.3 months, the objective response rate (ORR) was 70.9% (95% confidence interval [CI], 62–79), with a complete response or better in 52.1% of patients. The median duration of response (DoR) was 29.4 months (95% CI, 20–not evaluable [NE]). Median progression-free survival (PFS) was not reached, while median overall survival (OS) was 31.4 months (95% CI, 23.8–NE). Response rates were consistent across age groups, including patients aged ≥75 years, and were comparable between standard- and high-risk cytogenetic subgroups. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 88.0% of patients, with no new safety signals observed. 

Key learning: Longer-term follow-up data support the durability of responses to linvoseltamab 200 mg in heavily pretreated RRMM, with responses generally consistent across subgroups, including older patients and those with high-risk cytogenetic features.